https://onwar.se/ 2026-09-28T03:17:30+00:00 https://onwar.se/ https://onwar.se/lib/exe/fetch.php?media=wiki:dokuwiki.svg text/html 2026-09-27T22:59:02+00:00 Anonymous (anonymous@undisclosed.example.com) https://onwar.se/doku.php?id=surpass-2:tirzepatide_bests_semaglutide_in_hba1c_reduction_weight&rev=1790549942&do=diff The investigational glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide led to significant and superior HbA1c and body weight reductions for adults with type 2 diabetes vs. SURPASS-2 study data show. Additionally, a prespecified exploratory analysis showed 60% of participants on the highest, 15-mg dose of tirzepatide (Eli Lilly) achieved a composite endpoint of an HbA1c of 6.5% or lower and weight loss of 10% or greater with no reports of severe hypoglycemia, compared…